Log in to your Inderes Free account to see all free content on this page.
Active Biotech
0.492 SEK 0%Be the first to follow this company
Active Biotech develops drugs in disease areas such as cancer and inflammatory diseases where the immune system plays a crucial role. The company's project portfolio contains both small orally active immunomodulatory molecules and antibody-based immunotherapy. The company focuses on projects in specialist indications in disease areas such as hematological cancer, inflammatory eye diseases, and solid tumors.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ACTI
Daily low / high price
0.492 / 0.503
SEK
Market cap
178.01M SEK
Turnover
127.26K SEK
Volume
255K
Latest videos
Financial calendar
Interim report
22.08.2024
Interim report
07.11.2024
Annual report
13.02.2025
Interim report
08.05.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
MGA Holding AB | 28.1 % | 28.1 % |
Sjuenda Holding | 7.4 % | 7.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Active Biotech enters agreement for a clinical study of tasquinimod in myelofibrosis
Number of shares and votes in Active Biotech
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio